Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

Table 2 Guselkumab treatment effect on FACIT-Fatigue score at week 24 and week 52

	DISCOVER-1						DISCOVER-2
	Guselkumab 100 mg Q4W		Guselkumab 100 mg Q8W		Placebo to Guselkumab 100 mg Q4W at W24		Guselkumab 100 mg Q4W		Guselkumab 100 mg Q8W		Placebo to Guselkumab 100 mg Q4W at W24
	W 24	W 52	W 24	W 52	W 24	W 52	W 24	W 52	W 24	W 52	W 24	W 52
N	125	124	123	114	114	104	234	229	238	234	237	230
Observed mean change in FACIT-Fatigue score	5.6	6.9	5.9	7.5	2.6	6.6	7.0	7.7	8.0	8.9	3.8	7.5
(SD)	(7.8)	(8.4)	(10.4)	(9.6)	(8.3)	(9.4)	(8.6)	(9.1)	(9.9)	(9.5)	(9.0)	(9.4)
Cohen’s d effect size^a	0.55	0.68	0.52	0.66	0.26	0.65	0.75	0.84	0.81	0.91	0.41	0.80

FACIT Functional Assessment of Chronic Illness Therapy, Q4W every 4 weeks, Q8W every 8 weeks, SD standard deviation, W week
^aThe effect size of changes from baseline in FACIT-Fatigue scores, based on the observed data, was calculated by dividing the change in FACIT-Fatigue score from baseline by the SD of baseline scores [24]

ISSN: 1478-6362